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Association of serum total bilirubin with 
traditional and novel cardiovascular risk 
factors in apparently healthy subjects
ABSTRACT
Background. Bilirubin is considered as one of the strongest endogenous antioxidants. Recent studies 
suggest that high total bilirubin levels are associated with lower cardiovascular disease (CVD) risk. The 
aim of this study was to evaluate a the relationship between serum total bilirubin  and traditional as well 
as new risk factors for CVD in apparently healthy subjects.
Materials and methods. Study included 60 non-smoking, non-obese individuals (30 females, 30 males) with 
normal fasting glucose, aged 25–40 years. In all subjects basic anthropometric indicators (weight, WHR, 
BMI), blood pressure and laboratory tests: serum total bilirubin (Bil-T), lipid profile, CRP, plasma glucose, 
apolipoproteins AI and B and 25-hydroxyvitamin D were performed. Subjects were divided into two groups 
of relative CVD risk, specified by total bilirubin levels: low-risk (≥ 13.7 µmol/L) and high-risk (< 13.7 µmol/L).
Results. Total bilirubin ranged 6.16–32.15 µmol/L. In the study group 58% of subjects had Bil-T values above 
13.7 µmol/L. Higher values occurred more frequently in men (70%) and in subjects aged 30–40 years (71%). 
Statistically significant relationship between Bil-T, and traditional and new risk factors for CVD was found. 
Bil-T correlated negatively with non-HDL-C, LDL-C, systolic blood pressure as well as with apoB: apoAI 
ratio, apolipoprotein B, TC:HDL-C and TC. A weak positive correlation was found between serum Bil-T and 
HDL-C. Additionally, negative correlations with CRP and positive with 25-hydroxyvitamin D were observed 
in women. In subjects with low CVD risk, the prevalence of low LDL-C concentration (< 2.59 mmol/L) was 
nearly three-fold higher compared  with high-risk groups. Furthermore, in low-risk group the prevalence 
of serum CRP < 1 mg/L and HDL-C levels > 1.55 mmol/L was 2-fold and 3-fold higher, respectively,  and 
higher incidence of low apoB:apoAI values (<0.6) was observed.
Conclusions. Serum total bilirubin may play an important role in reducing the risk of CVD, therefore its 
assay seems to be valuable for more accurate assessment of cardiovascular risk in young, non-obese, 
non-diabetic individuals.
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Introduction
Cardiovascular disease is the leading cause of death 
worldwide. According to World Health Organization 
(WHO) in 2008 CVD was the cause of death of over 
17 million people, including 7 million due to coronary 
heart disease (CHD) and 6 million due to stroke, which 
accounted for 30% of all deaths. It is estimated that in 
2030 the mortality will increase up to 23 millions [1]. In 
Poland CVD is the cause of death in 43% of men and 
54% of women [2].
Atherosclerosis is  the main pathogenetic factor for 
CHD and stroke. It is a degenerative and inflammatory 
process, occurring mainly in medium and large arteries, 
associated with accumulation of fatty substances, frag-
ments of cells, calcium, mucopolysaccharides and col-
lagen fibers in the intima. Progression of atherosclerosis 
leads to partial or complete closure of the lumen, which 
causes organ ischemia and clinical symptoms. Many 
factors, both not modifiable (for example: gender, age, 
family history) and modifiable (smoking, low physical 
activity, obesity, dyslipidemias etc.), are relevant in the 
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pathogenesis of atherosclerosis and CVD. In the last 
decades particular attention is paid to the importance of 
the low grade inflammation and reactive oxygen species 
(ROS) in the endothelial dysfunction.
Proinflammatory cytokines (IL-6 and TNF-a, IL-1) 
and growth factors produced by macrophages infiltrat-
ing the vessel wall intensify endothelial dysfunction by 
stimulating the production of ROS [3]. Angiotensin II, 
which impairs the efficiency of the heart as a result of 
activation of the renin-angiotensin-aldosterone system, 
also shows the additional impact on the increased pro-
duction of ROS. Increased ROS cause oxidative stress, 
which leads to the activation of genes dependent redox 
potential. These multipotential genes are responsible 
for the production of proinflammatory cytokines which 
enhance the inflammatory reactions in the positive 
feedback mechanism. IL-1b and TNF-a have the ability 
to stimulate the production of adhesion molecules, pro-
coagulatory factors and other inflammatory mediators 
by endothelium and other cells. Moreover, IL-6 induces 
the expression of hepatic genes encoding acute phase 
reactants: C-reactive protein (CRP) and plasma amy-
loid-A (SAA) [4].
Bilirubin is a product of the oxidative metabolism of 
heme in mammals, originating primarily from hemoglo-
bin. Heme catabolism occurs in the microsomal fraction 
of the reticuloendothelial system of the spleen, by the 
enzyme called heme oxygenase [5]. Bilirubin is excreted 
in bile as polar compounds: mono- and di-glucuronide 
derivatives, formed after previous esterification with 
glucuronic acid [6]. Concentration of bilirubin in the 
blood is widely used as an indicator of liver and biliary 
tract function.
Heme degradation and synthesis of bilirubin 
are considered very important elements of the cell 
antioxidant defense. During this process heme mol-
ecules with prooxidative properties are neutralized 
(Fig. 1). Released iron, which may be a stimulant for 
the production of free radicals, is immediately bound 
by ferritin. Under normal concentrations, unbound 
bilirubin has scavenging properties to singlet oxygen. 
For certain peroxidases, in particular horseradish 
peroxidase and prostaglandin H synthase, in the 
presence of hydrogen peroxide or organic hydroxides 
bilirubin acts as a reducing agent, thereby reducing 
the number of potential oxidizing factors [7]. Bilirubin, 
as an antioxidant, can neutralize free radicals gener-
ated in vivo  as well as exogenous ones, for example 
in tobacco smoke. Studies in recent years show an 
inverse relationship between bilirubin and BMI, total 
cholesterol and LDL-C, suggesting that high levels 
of bilirubin can be a factor in reducing the risk of 
cardiovascular disease. The aim of this study was to 
evaluate the relationship between serum total bilirubin 
and traditional  as well as new risk factors for CVD in 
young, healthy subjects.
Figure 1. Antioxidative properties of bilirubin (modified according to [7])
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Subjects, materials and methods
Study included 60 non-obese (BMI < 30 kg/m2), 
non-smoking subjects (30 women, 30 men) aged 
25–40 years with normal fasting glucose (3.33– 
–5.49 mmol/L). Anthropometric measurements 
(weight, BMI, WHR) and medical history of chronic 
diseases were performed. Blood pressure was mea-
sured twice in 1–2 minutes intervals on dominant hand 
with the automatic blood pressure monitor Omron 
M6 Comfort (Omron Healthcare, Kyoto, Japan) which 
is clinically validated. Serum and fluoride plasma 
were collected in the morning (7.00–9.00 a.m.) after 
10–12 hours of fasting. Immediately after collection 
the samples were centrifuged in low temperature 
(4°C). After centrifugation, serum samples were 
divided into small aliquots —  one part was used 
for the routine laboratory measurements performed 
immediately on automatic analyzers and others 
were frozen in –70°C to avoid peptides degradation 
into further apolipoproteins and 25-hydroxyvitamin 
D assays. Serum samples were thawed only once 
in the room temperature, directly before measure-
ments. Laboratory tests: glucose, total bilirubin 
(T-Bil), C-reactive protein (CRP), total cholesterol 
(TC), HDL-cholesterol (HDL-C), triglycerides (TG), 
apolipoproteins AI and B (apoAI, apoB) and 25-hy-
droxyvitamin D (25(OH)D) were performed on Archi-
tect ci8200 (Abbott Laboratories, Abbott Park, USA) 
and Cobas e411 (Roche Diagnostics, Indianapolis, 
USA) analyzers. LDL cholesterol (LDL-C), non-HDL 
cholesterol (non-HDL-C) and atherogenic indexes 
(TC:HDL-C, apoB:apoAI) were calculated using prop-
er equations. The routine laboratory parameters were 
considered normal if they were as follows: plasma 
glucose 3.33–5.49 mmol/L (60–99 mg/dL); T-Bil 3.42– 
–20.52 µmol/L (0.2–1.2 mg/dL); CRP < 1 mg/L, 25(OH)D 
≥ 30 ng/mL. Reference values for lipid profile comply 
with the current ESC/EAS guidelines [8]. All laboratory 
measurements were performed in the Department of 
Laboratory Medicine, Nicolaus Copernicus University 
Collegium Medicum in Bydgoszcz, Poland. 
Statistical analysis was performed using STATISTI-
CA 10.0 software (StatSoft Inc. 2012). Data were pre-
sented as mean ± standard deviation (normal distribu-
tion) or median and 25th–75th percentile (non-Gaussian 
distribution). Differences between study groups were 
measured by t-Student, U-Mann-Whitney and ANOVA 
Kruskal-Wallis tests. P value < 0.05 was considered 
statistically significant.
The study was approved by the Bioethics Com-
mittee at the NCU Collegium Medicum in Bydgoszcz, 
Poland (No. KB 627/2010) and complied with the World 
Medical Association Declaration of Helsinki regarding 
ethical conduct of research involving human subjects. 
An informed written consent was obtained from all 
participants involved in this study.
Results
Table 1 shows clinical and biochemical character-
istics of the study group. Total bilirubin (T-Bil) concen-
tration ranged 6.16–32.15 µmol/L (0.36–1.88 mg/dL). 
In women significantly higher values of HDL-C, apoAI, 
25(OH)D and lower values of anthropometric indices, 
plasma glucose, TG and atherogenic indexes were 
found, compared to men. Despite higher median of 
T-Bil in men, compared to women, the difference was 
not statistically significant (p > 0.05). 
Relevant correlations between T-Bil and selected 
parameters were observed (Tab. 2). In the whole group 
total bilirubin showed moderate negative correlation 
with TC, apoB, apoB:apoAI and TC:HDL-C as well as 
strong inverse relationship with non-HDL-C (R = –0.54; 
p < 0.001), LDL-C (R= –0.56; p < 0.001) and systolic 
blood pressure (R = –0.59; p < 0.001). Weak but 
statistically significant positive correlation with HDL-C 
(R = 0.27; p < 0.05) was found. Similar association be-
tween T-Bil and lipid parameters was observed in both 
women and men, however, it seemed to be stronger 
in men. Moreover, correlations with CRP (R = –0.46; 
p < 0.05), and 25(OH)D (R = 0.41; p < 0.05) in women, 
and diastolic blood pressure (R = –0.6; p  <0.001) and 
WHR (R = –0.39; p < 0.05) in men were noticed.
Subjects were divided into two groups of car-
diovascular risk (Tab. 3) specified by total bilirubin 
concentration according to Endler et al. study [9]: 
low risk ≥ 13.7 µmol/L (≥ 0.8 mg/dL) and high 
risk < 13.7 µmol/L (< 0.8 mg/dL). In study group 58% 
of subjects had low CVD risk and this state  occurred 
more frequently in men (70%) and individuals aged 30– 
–40 years (71%). Significantly lower levels of systolic blood 
pressure, TC, LDL-C,  non-HDL-C, apoB and atherogenic 
indexes were found in subjects with T-Bil ≥ 13.7 µmol/L.
In the low CVD risk group a higher prevalence 
of potential anti-atherogenic factors was observed 
(Fig. 2 and 3). In subjects with T-Bil ≥ 13.7 µmol/L 
prevalence of LDL-C < 2.59 mmol/L (< 100 mg/dL) 
and CRP < 1 mg/L, considered as a indicators of low 
cardiovascular risk, was four-fold (p = 0.005) and 
two-fold (p = 0.03) higher, respectively, compared 
with individuals with lower T-Bil levels. Moreover, high 
values of HDL-C > 1.55 mmol/L (> 60 mg/dL)  occurred 
almost three times more frequently (p = 0.025) in the 
low CVD risk group.  As far as novel lipid risk factors are 
concerned, it was found that non-HDL-C < 3.37 mmol/L 
(< 130 mg/dL) was more prevalent (p = 0.006) in the 
low CVD risk group as well as the tendency to low apoB 
(< 0.6 g/L) and apoB:apoAI ratio (< 0.6) (both p = 0.05).
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Table 1. Clinical and biochemical characteristics of the study group
Variables All (n = 60)
Women
(n = 30) Men (n = 30) p*
Age (years) 30 (27–34 ) 30 (27–35) 30 (27–33) ns
BMI [kg/m2] 22.3 (20.8–25) 21 (20–22.3) 24.4 (21.7–25.9) < 0.001
WHR 0.79 (0.75–0.86) 0.76 ( ± 0.04) 0.86 ( ± 0.04) < 0.001
SBP [mm Hg] 118 (112–126) 117 (110–126) 121 (115–127) ns
DBP [mm Hg] 78 (74.5–81) 76 ( ±  6.5) 78 ( ± 3.4) ns
Glucose [mmol/L] 5.10 (4.77–5.35) 4.88 (4.61–5.10) 5.33 (5.10–5.49) < 0.001
CRP [mg/L] 0.6 (0.3–1.4 ) 0.5 (0.3–1.2) 0.8 (0.5–1.5) ns
T-Bil [µmol/L] 14.4 (10.8–19.1) 13.6 (9.6–18.8) 16.7 (12.3–19.5) ns
TC [mmol/L] 4.44 (3.94–4.71) 4.59 (3.96–4.87) 4.27 (3.83–4.66) ns
HDL-C [mmol/L] 1.46 (1.19–1.58) 1.54 (1.37–1.68) 1.28 (1.11–1.53) 0.0008
TG [mmol/L] 0.88 (0.69–1.09) 0.83 (0.63–0.98) 0.96 (0.75–1.41) 0.028
LDL–C [mmol/L] 2.46 ± 0.53 2.49 ± 0.45 2.44 ± 0.61 ns
Non-HDL-C [mmol/L] 2.90 ± 0.56 2.87 ± 0.47 2.93 ± 0.65 ns
TC:HDL-C 2.92 (2.63–3.61) 2.89 ± 0.47 3.36 ± 0.84 0.009
ApoAI [g/L] 1.42 (1.31–1.57) 1.57 ±  0.21 1.34 ± 0.15 <0.001
ApoB [g/L] 0.70 ± 0.13 0.65 (0.58–0.76) 0.71 (0.62–0.80) ns
ApoB:ApoAI 0.49 ± 0.12 0.44 ± 0.1 0.54 ± 0.13 0.002
25(OH)D [ng/mL] 19 ± 7.6 23 ± 6.7 15 ± 6.6 < 0.001
Results are presented as: mean ± SD or median (25–75%) 
*Differences men vs. women; ns – not significant; SBP/ DBP– systolic/diastolic blood pressure
Table 2. Correlation between total bilirubin and selected CVD risk factors
Variables All (n = 60) Women (n = 30) Men (n = 30)
WHR ns ns R = –0.38; p < 0.05
SBP R = –0.59; p < 0.001 R = –0.62; p < 0.001 R = –0.64; p < 0.001
DBP ns ns R = –0.60; p < 0.001
CRP ns R = –0.46; p < 0.05 ns
TC R = –0.46; p < 0.001 ns R = –0.75; p < 0.001
HDL-C R = 0.27; p < 0.05 ns R = 0.59; p < 0.05
LDL-C R = –0.56; p < 0.001 R = –0.46; p < 0.05 R = –0.75; p < 0.001
Non-HDL-C R = –0.54; p < 0.001 R = –0.41; p < 0.05 R = –0.78; p < 0.001
TC:HDL-C R = –0.45; p < 0.001 R = –0.38; p < 0.05 R = –0.76; p < 0.001
apoB R = –0.44; p < 0.001 R = –0.37; p < 0.05 R = –0.61; p < 0.001
apoB:apoAI R = –0.37; p < 0.05 ns R = –0.60; p < 0.001
25(OH)D ns R = 0.41; p < 0.05 ns
ns — not significant; SBP/ DBP— systolic/diastolic blood pressure
Discussion
In recent years several population-based studies 
indicated a relationship between total bilirubin con-
centration and cardiovascular disease risk in general 
population. The NHANES 1999–2004 Study reported 
that 1.71 µmol/L (0.1 mg/dL) increase in bilirubin 
concentration was associated with 9% reduced odds 
of stroke and with 10% reduced odds of an adverse 
stroke outcome [10]. In the Framingham Heart Study 
subjects with UGT1A1*28 allele, which encodes hepatic 
bilirubin uridine diphosphate-glucuronosyltransferase 
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high CVD risk (n = 25)
≥ 13.7
low CVD risk (n = 35)
Age (years) 31 (28–34) 29 (27–34) ns
BMI [kg/m2] 22.3 ± 2.7 23.1 ± 2.6 ns
WHR 0.81 ± 0.07 0.81 ± 0.06 ns
SBP [mm Hg] 125 (118–127) 115 (108–123) 0.015
DBP [mm Hg] 79 (74–82) 77 (75–80) ns
Glucose [mmol/L] 5.05 (4.88–5.27) 5.16 (4.77–5.38) ns
CRP [mg/L] 1.0 (0.5–1.5) 0.5 (0.3–1.0) ns
TC [mmol/L] 4.69 (4.56–4.89) 4.22 (3.73–4.45) < 0.001
HDL-C [mmol/L] 1.40 (1.11–1.55) 1.48 (1.24–1.61) ns
TG [mmol/L] 0.85 (0.72–1.08) 0.90 (0.69–1.09) ns
LDL-C [mmol/L] 2.79 ± 0.49 2.23 ± 0.42 < 0.001
Non-HDL-C [mmol/L] 3.22 ± 0.55 3.37 ± 0.44 < 0.001
TC:HDL-C 3.40 ± 0.81 2.90 ± 0.55 0.0026
ApoAI [g/L] 1.45 (1.36–1.56) 1.38 (1.31–1.59) ns
ApoB [g/L] 0.76 (0.68–0.87) 0.65 (0.58–0.71) 0.0032
ApoB:ApoAI 0.53 ± 0.13 0.46 ± 0.11 0.024
25(OH)D [ng/mL] 19.6 (14.82–22.9) 16.9 (12.07–24.24) ns
Results are presented as: mean ± SD or median (25–75%) 
ns — not significant; SBP/ DBP— systolic/diastolic blood pressure
Figure 2. Prevalence of low CRP, LDL-C and high HDL-C 
values depending on total bilirubin concentration
Figure 3. Prevalence of low non-HDL-C, apoB and 
apoB:apoAI values depending on total bilirubin concentration
and is responsible for higher bilirubin concentration, 
had significantly lower CVD and coronary heart disease 
risk (CHD) [11]. Moreover, the prevalence of CHD in 
patients with Gilbert syndrome is 2%, while in general 
population  it approximates to 12% [12]. In the study 
by Horsfall et al. [13] the risk of any CVD event, 
myocardial infarction and death resulting from any 
cause was 18%, 34% and 33%, respectively, higher in 
statin-treated patients with bilirubin level of 5 µmol/L 
(0.3 mg/dL) compared with those with a similar CVD 
risk profile and median bilirubin concentration of 
10 µmol/L (0.6 mg/dL). It was emphasized that clini-
31
Katarzyna Bergmann et al., Association of total bilirubin and CVD risk in healthy subjects
www.fmc.viamedica.pl
cians should pay particular attention to patients with 
bilirubin levels < 6 µmol/L (< 0.35 mg/dL). According 
to Endler et al. [9], subjects with T-Bil > 13.7 µmol/L 
(> 0.8 mg/dL) have a 40% reduction in prevalence 
of CHD after adjustment for factors such as: age, 
smoking, diabetes, hypertension, HDL, triglycerides, 
and BMI. However, this association was strong in men, 
while in women it was not significant. 
In our study a strong relationship between serum 
total bilirubin and traditional as well as novel CVD risk 
factors, mainly lipid parameters and blood pressure, 
was observed in both women and men. Kamisako et al., 
in the study including 270 Japanese men, indicated 
positive correlation of higher T-Bil levels with lower 
concentration of chylomicron remnants which have 
high proatherogenic properties [14]. In patients with 
Gilbert syndrome, concentration of total cholesterol, 
triglycerides, IDL, VLDL and LDL was significantly lower 
compared with controls [15]. In the study by de Sauvage 
Nolting et al. [16] significantly lower T-Bil levels were 
found in patients with CVD and familial hypercholester-
olemia compared with controls (0.57 vs. 0.61 mg/dL; 
p < 0.05). After statin treatment a significant decrease 
in TC, LDL-C and TG as well as an increase in HDL-C 
and total bilirubin concentration was reported. A neg-
ative correlation between T-Bil and BMI, LDL-C and 
TC was observed by McArdle et al. [17]. Total bilirubin 
concentration was negatively associated with glycated 
hemoglobin (HbA1c) independently of plasma glucose, 
age, obesity, and inflammation in non-diabetic Jap-
anese [18]. Moreover, lower T-Bil levels in smoking 
subjects and negative correlation with CRP in smoking 
men and non-smoking women were found.
Recent studies suggest that bilirubin shows cardi-
oprotective effects in coronary arteries. In acute myo-
cardial stress, including infarction with ST elevation, 
an increase in total bilirubin and many cytokines and 
neurohumoral mediators levels is detected. Elevated 
T-Bil is considered to be a compensation for increased 
production of inflammatory mediators. In conditions 
of severe stress, activation of the heme oxidase is ob-
served. The degree of HO-1 activation is closely linked 
to the intensity of the inflammatory response, caused 
by myocardium necrosis [19]. In this process, there is 
a severe degradation of heme particles and increased 
production of T-Bil. Heme degradation products and 
bilirubin have a protective effect due to their antioxidant 
properties. Therefore, determining the concentration of 
total bilirubin might be useful in the evaluation of CVD risk 
and its outcomes in apparently healthy subjects as well 
as in cardiological patients. Due to the limitations of our 
study, including relatively small study group, the results 
need to be confirmed in a large population-based study.
Conclusions
The significant correlation between total bilirubin and 
traditional as well as novel CVD risk factors, which is pre-
sented in our study, denotes its potential role as a new 
additional risk indicator in young, non-obese, non-dia-
betic subjects. Higher T-Bil concentration is associated 
with lower values of proatherogenic factors and higher 
values of cardioprotective agents which indicates that 
the determination of total bilirubin should be included for 
more accurate cardiovascular disease risk assessment . 
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